Skip to main content
. Author manuscript; available in PMC: 2010 Oct 20.
Published in final edited form as: Cardiovasc Res. 2007 Sep 22;77(1):44–53. doi: 10.1093/cvr/cvm026

Figure 5.

Figure 5

(A) Thrombopoietin dose–response studies in vivo. Percent infarction in the left ventricle following a 15 min treatment with thrombopoietin (0.005, 0.05, or 0.5 μg/kg iv) prior to 30 min of regional ischaemia and 180 min of reperfusion. (B) Phase of action of thrombopoietin. Infarct size was determined after 30 min regional ischaemia and 120 min reperfusion. Data are mean ± SD, n = 6 hearts per group. *P < 0.05, thrombopoietin vs. drug-free control.

HHS Vulnerability Disclosure